| |
19thNationwide survey (2005–2006)
|
First cohort (2004–2008)
|
p-value
|
|---|
|
Total
|
20,475
|
100.0
|
126
|
100.0
| |
|
Dosage of IVIG
|
Cases
|
%
|
Cases
|
%
| |
|
2 g/kg
|
11,612
|
56.7
|
3
|
2.1
|
0.001
|
|
1 g/kg/day × 2 d
|
4,800
|
23.4
|
3
|
2.1
|
0.001
|
|
400 mg/kg/day × 5 d
|
231
|
1.1
|
95
|
75.4
|
0.001
|
|
Various dosages of IVIG
|
879
|
4.3
|
0
|
0
|
0.01
|
|
Aspirin alone (no IVIG)
|
2,866
|
14.0
|
25
|
19.8
|
0.07
|
|
Dalteparin
|
0
|
0
|
126
|
100.0
| |
|
Age (months)
|
-*
|
22 (0–167)
| |
|
Male sex
|
11,892 (58.1%)
|
68 (54.0%)
|
0.37
|
- KD: Kawasaki disease; NUNH Hospital: Nihon University Nerima-Hikarigaoka Hospital; IVIG: intravenous immunoglobulin.
- Dalteparin was administered until the patient was afebrile, clinically improving, and/or showed a C-reactive protein (CRP) < 1.0 mg/dL.
- Data are median (range), n (%).
- *The highest prevalence was observed among those aged 6–8 months [17].
